Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) is a pioneering biopharmaceutical company dedicated to revolutionizing RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™). Their innovative approach merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases that were previously unreachable with existing RNA therapies. They are at the forefront of developing therapies for serious genetic conditions, predominantly focusing on rare muscle diseases.
Avidity's leading clinical programs include:
- AOC 1001 (Del-desiran): Targeting Myotonic Dystrophy Type 1 (DM1), a disease with no approved therapies. Del-desiran has shown promising long-term data from the MARINA-OLE™ trial, demonstrating reversal of disease progression in patients. The global Phase 3 HARBOR™ trial is set to begin, with video hand opening time (vHOT) as the primary endpoint.
- AOC 1044: Aimed at Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping. Recently, it achieved Rare Pediatric Disease and Orphan Drug designations from the FDA and EMA. Positive preliminary data has been reported from the Phase 1/2 EXPLORE44™ clinical trial.
- AOC 1020: Focused on Facioscapulohumeral Muscular Dystrophy (FSHD). Clinical data from the Phase 1/2 FORTITUDE™ trial is expected soon.
Avidity is also advancing its pipeline to include cardiology and immunology programs, aiming to target a broader range of diseases. The company has garnered support and collaborations with top-tier investors and strategic partners, enhancing its capability to deliver groundbreaking treatments.
With headquarters in San Diego, CA, Avidity Biosciences is committed to transforming lives through innovative RNA therapeutics. For more information, visit www.aviditybiosciences.com.
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) secures funding from various investors and plans to raise $400 million through a private placement. The company expects its cash reserves to last until late 2026. AOC 1001 data from MARINA-OLE™ will be presented at an investor event on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.92%
Tags
-
News
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) reported financial results for Q4 2023 and highlighted progress. They plan to initiate the global Phase 3 HARBOR™ trial for AOC 1001 for DM1, share data from clinical programs for FSHD and DMD44, and advance cardiology and skeletal muscle programs. Avidity is in a strong financial position with $595 million at the end of 2023 and a cash runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.92%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) announces participation in upcoming healthcare conferences to discuss RNA therapeutics. The company will be present at TD Cowen 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted stock options and RSUs to new non-executive employees under the 2022 Inducement Plan. The options have an exercise price of $13.98 per share and will vest over four years, while the RSUs will vest in four equal installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary
Avidity Biosciences Receives Rare Pediatric Disease Designation from FDA for AOC 1044 in Duchenne Muscular Dystrophy Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the presentation of new data from MARINA-OLE™ trial at the 2024 MDA Conference. Dr. John W. Day will join Avidity management for a live webcast event. The company will showcase multiple posters on rare muscle diseases, including AOC 1001 efficacy and safety data. Avidity is focused on RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2022 Inducement Plan. The options have an exercise price of $10.16 per share, with vesting over four years. The RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date. The awards are subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of a stock option agreement or RSU agreement, as applicable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) plans to initiate the global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024. The company will report data from all three ongoing clinical programs in 2024, including AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H. Avidity also announced the appointment of Eric B. Mosbrooker as Chief Strategy Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $8.40 per share and will vest over four years, while the RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) announces positive AOC 1044 data in healthy volunteers for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping. AOC 1044 delivered up to 50-times greater concentrations of PMO in skeletal muscle following a single dose compared to peptide conjugated PMOs in healthy volunteers. The company plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.28%
Tags
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
The current stock price of Avidity Biosciences (RNA) is $43.25 as of November 22, 2024.
What is the market cap of Avidity Biosciences (RNA)?
The market cap of Avidity Biosciences (RNA) is approximately 5.2B.
What is Avidity Biosciences, Inc.?
Avidity Biosciences, Inc. is a biopharmaceutical company pioneering RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™) to treat serious genetic diseases.
What are Antibody Oligonucleotide Conjugates (AOCs™)?
AOCs™ combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases previously unreachable with existing RNA therapies.
What is AOC 1001 (Del-desiran)?
AOC 1001 (Del-desiran) is Avidity's lead product candidate for treating Myotonic Dystrophy Type 1 (DM1). It has shown promising results in clinical trials and is entering global Phase 3 HARBOR™ trial.
What are the key clinical programs of Avidity Biosciences?
The key clinical programs include AOC 1001 for DM1, AOC 1044 for Duchenne Muscular Dystrophy (DMD) with exon 44 skipping, and AOC 1020 for Facioscapulohumeral Muscular Dystrophy (FSHD).
What designations has AOC 1044 received?
AOC 1044 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA and EMA for its potential to treat Duchenne Muscular Dystrophy (DMD) with exon 44 skipping.
What is the significance of the MARINA-OLE™ trial?
The MARINA-OLE™ trial demonstrated that AOC 1001 (Del-desiran) can reverse disease progression in Myotonic Dystrophy Type 1 (DM1) patients, showing improvements in key metrics such as video hand opening time (vHOT) and muscle strength.
What other areas is Avidity Biosciences expanding into?
In addition to rare muscle diseases, Avidity Biosciences is expanding its pipeline to include cardiology and immunology programs through internal discovery efforts and key partnerships.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in San Diego, CA.
How is Avidity Biosciences funded?
Avidity Biosciences is supported by top-tier investors and partnerships, recently completing an oversubscribed equity raise of $400 million, securing its financial position to fund operations into late 2026.
How can I learn more about Avidity Biosciences?
For more information, visit their official website at www.aviditybiosciences.com.
Avidity Biosciences, Inc.
Nasdaq:RNA
RNA Rankings
RNA Stock Data
5.18B
112.41M
4.83%
106.29%
12.29%
Biotechnology
Pharmaceutical Preparations
United States of America
SAN DIEGO